Actions

Immnophenotypic markers in AML: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 14: Line 14:
!colspan="2" style = "background:lightgrey; border:solid"| '''Pattern 1:'''</br>A myeloid '''lineage-defining''' marker pattern is present '''and''' No lineage-defining markers of T or B cells are present.
!colspan="2" style = "background:lightgrey; border:solid"| '''Pattern 1:'''</br>A myeloid '''lineage-defining''' marker pattern is present '''and''' No lineage-defining markers of T or B cells are present.
|-
|-
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1"|'''There are two potential marker patterns that define definite myeloid lineage in AML'''
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1"|'''There are two potential marker patterns that allow definite myeloid lineage assignment in AML'''
|-
|-
|colspan="1" style = "font-size:90%; color:black; width:15%;" |Definite evidence of '''granulocytic''' maturation
|colspan="1" style = "font-size:90%; color:black; width:15%;" |Definite evidence of '''granulocytic''' maturation
|colspan="1" style = "font-size:90%;"|[[MPO]] is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes).
|colspan="1" style = "font-size:90%;"|[[MPO]] is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes).
|-
|-
|colspan="1" style = "font-size:90%; color:black;" |'''Monocytic lineage''' can be assigned.
|colspan="1" style = "font-size:90%; color:black;" |Definite evidence of '''monocytic''' maturation
|colspan="1" style = "font-size:90%;"|This requires detection of at least two of: [[CD14]], [[CD11c]], [[CD64]], [[NSE]], lysozyme*
|colspan="1" style = "font-size:90%;"|This requires detection of at least two of: [[CD14]], [[CD11c]], [[CD64]], [[NSE]], lysozyme*
|-
|-

Revision as of 17:32, 20 December 2023



Table: Marker patterns that allow definite diagnosis of acute myeloid leukaemia


Pattern 1:
A myeloid lineage-defining marker pattern is present and No lineage-defining markers of T or B cells are present.
There are two potential marker patterns that allow definite myeloid lineage assignment in AML
Definite evidence of granulocytic maturation MPO is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes).
Definite evidence of monocytic maturation This requires detection of at least two of: CD14, CD11c, CD64, NSE, lysozyme*


Pattern 2:
At least two myeloid lineage-associated markers are present and there are no lineage defining markers of T or B cells
and no more than one T-cell or B-cell lineage-associated marker is present
A number of markers can be viewed as myeloid lineage associated
CD117 An early marker of myeloid lineage, seen in up to 80% of AML and vauable in recognising more primitive differentaiion forms (note that aberrant expression is seen in up to 20% of ALL cases)
CD33 A good marker for AML, particularly for those cases with granulocytic maturation, CD33 is often less strongly expressed in AML with monocytic dfferentiation and strongly expressed in APL.
CD13 A good lineage marker for AML that is acquired a little later in differentation than CD117 or CD33; expression of CD13 is often higher than CD33 in AML with monocytic differentiation.